if operators are busy, call again, or go to loveshriners.org to give right away. thank you!ncine: globally, more than 1 billion people are thought to be obese. it's a crucial market for weight loss drug makers like novo nordisk, but challenges remain. the company's patents expire in the u.s. and the e.u. at the end of the next decade, and rival drugs are already emerging, like zepbound by eli lilly. i asked the chief executive, lars fruergaard jØrgensen, about regulatory pressures and future growth. so, how do you think about pricing? again, you must have gotten some difficult questions from governments, but also, this goes back to innovation. lars: most products are priced according to the value they bring. and i feel really good about the value of our medicines, what they bring to the individual patient, but also the value to the health care system. and we have, today, health care systems around the world who were typically designed for acute care. but finding that 80% of the cost in the health care system is linked to chronic care. and we have portfolio products that are